LandMark White to acquire Taylor Byrne Holdings

Published 08-OCT-2018 12:07 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

LandMark White (ASX:LMW) has made an offer to acquire all of the issued shares in Taylor Byrne Holdings Pty Ltd. this morning.

The Offer Information Statement (OIS) will see shareholders in Taylor Byrne Holdings receive ordinary shares in LMW as partial consideration of their shares in the company.

Of course this remains a speculative stock and investors should seek professional financial advice if considering this company for their portfolio.

The Offer

The offer opens on 10.00am AEST October 8 and will close upon the earlier of 5.00pm AEST on October 15 2018 (or upon LMW receiving valid applications for all of the Shares offered under this document).

The offer made is for total consideration value of $10.3 million, payable as:

  • $5.15 million cash consideration and
  • 8,583,333 shares in LMW, each at a deemed issue price of $0.60 (consideration shares)

These consideration shares will be subject to voluntary escrow arrangements, under which 25% of the consideration shares will be released at the expiry of consecutive periods of 6 months, the first of which will commence on the first anniversary of completion.

About Taylor Byrne

Taylor Byrne is a valuation and property consultancy firm operating in Queensland and New South Wales.

The company has now expanded to 25 offices, making it one of the largest single entity valuation firms in Australia.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X